The diabetes drugs known as the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have demonstrated clear benefit for cardiovascular disease associated with diabetes. Researchers wanted to take a closer look at one GLP-1 RA medication, semaglutide, and determine how many years can be added to a patient’s life with this drug’s addition. Read more